Palonosetron Hydrochloride

PALONOSETRON HYDROCHLORIDE

Manufacturer: Mylan Institutional LLC

Score: 141.0

Quick Summary

Palonosetron is a serotonin-3 (5-HT3) receptor antagonist used for the prevention of nausea and vomiting associated with cancer chemotherapy and postoperative nausea and vomiting. It is available in a 0.25mg/5mL single-dose vial and is administered intravenously. The recommended dosage varies based on the condition being treated, with adults typically receiving 0.25mg for chemotherapy-induced nausea and vomiting and 0.075mg for postoperative nausea and vomiting. Pediatric patients require a higher dose, with a maximum of 1.5mg. The drug has been shown to be effective in clinical trials, but may have adverse reactions such as headache, constipation, and QT prolongation. Special considerations are needed for use in pregnancy, nursing mothers, pediatric patients, and geriatric patients.

Key Clinical Findings and Indications

Prevention of nausea and vomiting associated with cancer chemotherapy
Prevention of postoperative nausea and vomiting
Effective in clinical trials for chemotherapy-induced nausea and vomiting
Approved for use in pediatric patients aged 1 month to less than 17 years

Important Safety Information

Warning

Hypersensitivity reactions, including anaphylaxis, have been reported

Contraindications

Hypersensitivity to palonosetron or any of its components

Adverse Reactions

Headache
Constipation
QT prolongation
Bradycardia

Dosing Recommendations

General Guidance

No dose adjustment is required for geriatric patients

Chemotherapy-induced nausea and vomiting

Adult Dose

0.25mg as a single dose

Pediatric Dose

20mcg/kg (maximum 1.5mg) as a single dose

Postoperative nausea and vomiting

Adult Dose

0.075mg as a single dose

Pediatric Dose

Not established

Special Population Considerations

Pregnancy

No available data on use in pregnant women
Animal studies show no effects on embryo-fetal development

Nursing Mothers

No data on presence in human milk
Caution advised

Pediatric Use

Approved for use in pediatric patients aged 1 month to less than 17 years
Higher dose required compared to adults

Geriatric Use

No overall differences in safety or effectiveness observed
Greater sensitivity in some older individuals cannot be ruled out

Similar Drugs

Ondansetron Hydrochloride

ONDANSETRON HYDROCHLORIDE

Quality Care Products LLC

Similarity: 70.1%

AKYNZEO

NETUPITANT AND PALONOSETRON

Helsinn Therapeutics (U.S.), Inc.

Similarity: 65.8%

Fluoxetine HCl

FLUOXETINE HCL

Almatica Pharma Inc.

Similarity: 60.5%